Karl-Dimiter Bissig, M.D., Ph.D.
Department of Molecular and Cellular Biology
Stem Cells and Regenerative Medicine Center
- M.D., School of Medicine, University of Bern, Switzerland
- Ph.D., School of Medicine, University of Bern, Switzerland
- Postdoctorate, Salk Institute for Biological Studies, La Jolla, CA
- Induced pluripotent stem (iPS) cell technology and cellular programming
- Cell therapy for liver disease
- Preclinical animal models for cell therapy
- Human liver chimeric mice for propagation of human pathogens (HBV, HCV, P. falciparum, etc.)
- Cell therapy for the liver
- Metabolic liver disease
- Viral hepatitis (HCV, HBV)
- Huang P, He Z, Ji S, Sun H, Xiang D, Liu C, Hu Y, Wang X, Hui L. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature. 2011 May 11. [Epub ahead of print]
- Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol. 2011 May;13(5):497-505.
- Ruiz S, Panopoulos AD, Herrerías A, Bissig KD, Lutz M, Berggren WT, Verma IM, Izpisua Belmonte JC. A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Curr Biol. 2011 Jan 11;21(1):45-52.
- Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest. 2010 Mar 1;120(3):924-30.
- Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20507-11.